The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
The discontinuation of oral or rectal 5-ASA monotherapy in patients with UC is associated with an increased risk of relapse. The data for discontinuation of 5-ASA in patients with UC or CD who are on immunomodulators and/or biologics is marginal for a meta-analysis; considering this limitation, these patients do not seem to have an increased risk of relapse upon discontinuation of 5-ASA, suggesting that monitored withdrawal may be a viable strategy.
Authors
- Rupert W. Leong (ORCID: https://orcid.org/0000-0001-5944-3488)
- Alice Kerkham (ORCID: https://orcid.org/0009-0005-8447-1014)
- Yvonne Tran (ORCID: https://orcid.org/0000-0002-1741-4205)
- David T. Rubin (ORCID: https://orcid.org/0000-0001-5647-1723)
- Cynthia H. Seow (ORCID: https://orcid.org/0000-0002-1551-9054)
- Arteen Arzivian (ORCID: https://orcid.org/0009-0009-5642-8069)
Institutions
- University of Calgary (CA)
- Nepean Hospital (AU)
- University of Chicago (US)
- Macquarie University (AU)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1093/ibd/izaf277
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00